Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Watson Says Received Favorable Ruling Over Generic Sanctura XR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2012 | 12:19am CEST

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ACTAVIS INC
05/06DJEndo Cuts Annual Guidance on Impairment Charge
05/03DJPfizer Reports Rock-Solid Quarter, Sees Stronger Year Ahead
05/03DJPfizer Guides Higher, Mulls Breakup of Company
04/27DJNew Tax Inversion Rules Complicate Equipment-Maker Deal
04/25DJJOSEPH PAPA : Valeant Names Joseph Papa as New CEO
04/22DJGlaxo's CEO Hunt Focuses on R&D -- WSJ
04/21DJGlaxo Investors Want CEO Who Can Revitalize R&D
04/07DJEUROPE MARKETS : European Stocks End Lower As Growth Concerns Linger
04/07DJLONDON MARKETS : FTSE 100 Rally Loses Steam As Oil Prices Drop
04/07DJAllergan Completes Licensing Deal After Pfizer Bid Collapses
Advertisement
Income Statement Evolution
More Financials